Literature DB >> 16930495

Acute urinary retention: who is at risk and how best to manage it?

Anand Patel1, Christopher Chapple.   

Abstract

In recent years, we have begun to understand the progressive nature of benign prostatic hyperplasia. By careful analysis of population studies and clinical trials, we can determine the factors most likely to predict progression to one of its most distressing complications, acute urinary retention. Acute urinary retention is a common urologic emergency and causes significant suffering, although rarely has it any serious consequences. Using our knowledge regarding the progression of benign prostatic hyperplasia, new treatment modalities are being assessed for their effectiveness at halting progression and ultimately preventing this distressing condition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930495     DOI: 10.1007/s11934-996-0003-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  50 in total

Review 1.  Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.

Authors:  E David Crawford
Journal:  BJU Int       Date:  2005-06       Impact factor: 5.588

2.  Natural history of prostatic obstruction. A prospective survey.

Authors:  A A Craigen; J B Hickling; C R Saunders; R G Carpenter
Journal:  J R Coll Gen Pract       Date:  1969-10

Review 3.  Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions.

Authors:  Claus G Roehrborn
Journal:  Urology       Date:  2002-06       Impact factor: 2.649

4.  Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.

Authors:  S A McNeill; T B Hargreave; Claus G Roehrborn
Journal:  Urology       Date:  2005-01       Impact factor: 2.649

5.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

6.  5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.

Authors:  P Boyle; C Roehrborn; R Harkaway; J Logie; J de la Rosette; M Emberton
Journal:  Eur Urol       Date:  2004-05       Impact factor: 20.096

7.  Prostate size influences the outcome after presenting with acute urinary retention.

Authors:  Alan S McNeill; Syed Rizvi; Derek J Byrne
Journal:  BJU Int       Date:  2004-09       Impact factor: 5.588

8.  Natural history of benign prostatic hypertrophy and acute urinary retention.

Authors:  J D Birkhoff; A R Wiederhorn; M L Hamilton; H H Zinsser
Journal:  Urology       Date:  1976-01       Impact factor: 2.649

9.  Symptoms and signs predictive of the voiding pattern after acute urinary retention in men.

Authors:  P Klarskov; J T Andersen; C F Asmussen; J Brenøe; S K Jensen; I L Jensen; P Lund; A Schultz; T Vedel
Journal:  Scand J Urol Nephrol       Date:  1987

Review 10.  Acute urinary retention in men: the risks and outcomes with medical therapy.

Authors:  Timothy B Hargreave; Alan S McNeill
Journal:  Curr Urol Rep       Date:  2005-07       Impact factor: 2.862

View more
  1 in total

1.  Bladder outlet obstruction in men with acute urinary retention: an urodynamic study.

Authors:  Maximilian Rom; Matthias Waldert; Hans Christoph Klingler; Tobias Klatte
Journal:  World J Urol       Date:  2013-01-17       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.